G&E Herbal Biotechnology Co., Ltd. (TPEX: 4911)

G&E Herbal Biotechnology Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	83.82	72.4	7.38	-19.88	-14.3	-23.37
Depreciation & Amortization	9.55	9.33	9.4	9.33	9.21	9.22
Other Amortization	-	-	-	0	0	0
Loss (Gain) From Sale of Assets	0.33	0.01	0	0.02	0.01	0
Other Operating Activities	20.82	17.98	0.71	1.67	-2.51	-4.15
Change in Accounts Receivable	-2.34	-14.19	4.38	1.08	-2.22	-3.74
Change in Inventory	3.8	1.74	-5.69	-2.85	0.14	3.13
Change in Accounts Payable	0.93	-2	2.47	-0.35	0.35	-0.03
Change in Unearned Revenue	11.56	23.39	71.39	0.28	0	0.08
Change in Other Net Operating Assets	4.68	4.82	9.92	1.52	10.09	-0.56
Operating Cash Flow	133.14	113.48	99.96	-9.19	0.77	-19.41
Operating Cash Flow Growth	43.56%	13.52%	-	-	-	-
Capital Expenditures	-3.84	-5.52	-2.95	-1.77	-5	-6.41
Sale (Purchase) of Intangibles	-0.07	-	-0.01	-0.22	-1.77	-
Investment in Securities	-97.55	-82.04	5.4	9	15.9	18.5
Other Investing Activities	-1.05	-0.87	0.07	-	-0.01	0.02
Investing Cash Flow	-102.5	-88.43	2.51	7.01	9.13	12.11
Long-Term Debt Repaid	-	-0.12	-	-	-	-
Net Debt Issued (Repaid)	-0.46	-0.12	-	-	-	-
Other Financing Activities	-	-	-	-	-	-0.79
Financing Cash Flow	-0.46	-0.12	-	-	-	-0.79
Net Cash Flow	30.18	24.94	102.47	-2.18	9.9	-8.08
Free Cash Flow	129.3	107.96	97.01	-10.96	-4.23	-25.81
Free Cash Flow Growth	48.99%	11.29%	-	-	-	-
Free Cash Flow Margin	61.24%	59.50%	150.15%	-44.61%	-14.98%	-147.05%
Free Cash Flow Per Share	2.19	1.83	1.64	-0.19	-0.07	-0.44
Cash Interest Paid	0.02	0	-	-	-	-
Cash Income Tax Paid	0.08	0.02	-	-	-	-
Levered Free Cash Flow	113.95	67.88	93.19	-5.52	-7.17	-21.93
Unlevered Free Cash Flow	113.97	67.88	93.19	-5.52	-7.17	-21.93
Change in Net Working Capital	-49.97	-13.64	-83.33	0.64	-0.05	6.82

Source: S&P Capital IQ. Standard template. Financial Sources.